Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review

被引:89
作者
Garcia-Pavon, Susana [1 ]
Yamazaki-Nakashimada, Marco A. [2 ]
Baez, Milton [3 ]
Borjas-Aguilar, Karla L. [2 ]
Murata, Chiharu [4 ]
机构
[1] Naval Hosp High Special, Allergy & Immunol Dept, Mexico City, DF, Mexico
[2] Natl Inst Pediat, Dept Clin Immunol, Mexico City, DF, Mexico
[3] Natl Inst Pediat, Pediat Private Practice, Mexico City, DF, Mexico
[4] Natl Inst Pediat, Res Methodol Dept, Mexico City, DF, Mexico
关键词
Kawasaki disease; macrophage activation syndrome; secondary hemophagocytic lymphohistiocytosis; hyperferritinemia; JUVENILE IDIOPATHIC ARTHRITIS; CORONARY-ARTERY ANEURYSMS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; DIFFERENTIAL-DIAGNOSIS; CHILDREN; MANIFESTATION; GUIDELINES; ANAKINRA; EFFICACY; CRITERIA;
D O I
10.1097/MPH.0000000000000872
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis, is a rare and potentially fatal complication of Kawasaki disease (KD). We report 2 cases, performed a literature search, and analyze the characteristics of MAS associated with KD. A total of 69 patients were evaluated, 34 reported the date of the diagnosis of MAS and KD, 6% had a diagnosis of MAS before KD, 21% had a simultaneous presentation, and 73% had the diagnosis of MAS after KD. Different treatment approaches were observed with corticosteroids administered in 87%, cyclosporine in 49%, etoposide (VP-16) in 39%, and monoclonal anti-TNF in 6% of cases. Coronary abnormalities were especially high in this group of patients (46%) and 9 patients died (13%). The persistence of fever with splenomegaly, hyperferritinemia, thrombocytopenia, and elevated aspartate aminotransferase (AST) should prompt the consideration of MAS complicating KD.
引用
收藏
页码:445 / 451
页数:7
相关论文
共 54 条
[1]   Hemophagocytosis complicating Kawasaki disease [J].
Al-Eid, W ;
Al-Jefri, A ;
Bahabri, S ;
Al-Mayouf, S .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2000, 17 (04) :323-329
[2]  
Atteritano M, 2012, EUR REV MED PHARMACO, V16, P1414
[3]   Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood [J].
Avcin, Tadej ;
Tse, Shirley M. L. ;
Schneider, Rayfel ;
Ngan, Bo ;
Silverman, Earl D. .
JOURNAL OF PEDIATRICS, 2006, 148 (05) :683-686
[4]   Macrophage Activation Syndrome: A Potentially Fatal Complication of Kawasaki Disease [J].
Bose, Kallol ;
Saha, Sudip ;
Saha, Prabir ;
Mondal, Piyasi .
ARCHIVES OF RHEUMATOLOGY, 2015, 30 (02) :178-180
[5]   Adjunctive therapies for Kawasaki disease [J].
Campbell, Anita J. ;
Burns, Jane C. .
JOURNAL OF INFECTION, 2016, 72 :S1-S5
[6]   Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki disease [J].
Chen, Xi ;
Zhao, Zhen-Wen ;
Li, Lin ;
Chen, Xue-Jun ;
Xu, Hui ;
Lou, Jin-Tu ;
Li, Lin-Jie ;
Du, Li-Zhong ;
Xie, Chun-Hong .
LIPIDS IN HEALTH AND DISEASE, 2015, 14
[7]   HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AT INITIATION OF KAWASAKI DISEASE AND THEIR DIFFERENTIAL DIAGNOSIS [J].
Chen, Yinghu ;
Shang, Shiqiang ;
Zhang, Chenmei ;
Liu, Tao ;
Yang, Zihao ;
Tang, Yongmin .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2010, 27 (03) :244-249
[8]  
Choi Ui-Yoon, 2017, Semin Arthritis Rheum, V46, pe17, DOI 10.1016/j.semarthrit.2016.08.007
[9]  
Cummings Christy, 2008, Pediatr Infect Dis J, V27, P1116, DOI 10.1097/INF.0b013e31817ecb6d
[10]  
Dapul-Hidalgo G, 2010, ANN ALLERG ASTHMA IM, V105, pA62